Multiple inflammatory pathway components including NF-κB signaling and adenosine uptake

This entry describes a multi-target pharmacological profile rather than a single molecular entity, primarily characterized by the modulation of the Nuclear Factor kappa B (NF-κB) signaling pathway and the inhibition of cellular adenosine uptake (Weyrich et al., 2005). The mechanism typically involves the blockade of Equilibrative Nucleoside Transporters (ENTs), such as SLC29A1, which increases extracellular adenosine concentrations (Young et al., 2013). Elevated adenosine then acts on G-protein coupled adenosine receptors to suppress the activation of NF-κB, a master regulator of the inflammatory response (Liu et al., 2017). This dual action is a hallmark of drugs like dipyridamole, which are used for their anti-thrombotic and anti-inflammatory properties. By targeting these components, therapeutic agents can reduce the production of pro-inflammatory cytokines and modulate vascular tone, making this profile relevant for treating cardiovascular diseases and systemic inflammatory conditions. This integrated pathway plays a crucial role in regulating systemic inflammation, vascular homeostasis, and platelet function.

Other names

NF-kappaB signaling pathwayAdenosine transportEquilibrative nucleoside transporter 1 (ENT1) inhibitionSLC29A1 inhibitionDipyridamole target profile

Inhibition of Equilibrative Nucleoside Transporters (ENTs) leads to increased extracellular adenosine, which activates adenosine receptors (A2A/A2B), subsequently inhibiting NF-κB activation and pro-inflammatory cytokine production (Weyrich et al., 2005; Liu et al., 2017).